Sumoson, Riza H.

HRN: 04-91-15  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/16/2024
CO-AMOXICLAV 625MG (TAB)
07/16/2024
07/23/2024
ORAL
625mg
BID
NSVD Post Episioraphy
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: